文献速递心脑血管急症

急性冠脉综合征PCI术后替格瑞洛与氯吡格雷净不良临床事件比较

Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
PubMed 文献 · JAMA · 2020-01-01
一句话结论ACS行PCI患者中,替格瑞洛较氯吡格雷12个月净不良临床事件无显著差异,但出血和呼吸困难风险显著更高。

主要终点12个月净不良临床事件(NACE)在替格瑞洛与氯吡格雷间无显著差异(15.1% vs 14.6%;汇总HR 1.05,95%CI 1.00-1.10;替格瑞洛组出血事件(2.1% vs 1.6%;汇总HR 1.35,95%CI 1.13-1.61;汇总HR 1.21,95%CI 1.17-1.26;全因死亡和缺血事件无显著差异。

要点

  • 95.5%的患者同时服用阿司匹林联合替格瑞洛或氯吡格雷。

适用人群与场景

  • 因急性冠脉综合征(ACS)行经皮冠状动脉介入治疗(PCI)并接受替格瑞洛或氯吡格雷的患者。
  • 数据来源于美国两个电子健康记录数据库和一个韩国全国数据库,2011年11月至2019年3月。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 95.5%的患者同时服用阿司匹林联合替格瑞洛或氯吡格雷。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文指出不能排除未测量混杂因素的可能性,需要进一步研究确定替格瑞洛在该人群中是否比氯吡格雷更有效。

对床旁实践的改变

  • 在ACS行PCI的常规临床实践中,替格瑞洛与氯吡格雷12个月NACE无显著差异,但替格瑞洛组出血和呼吸困难风险显著更高。
  • 原文指出因不能排除未测量混杂因素,需进一步研究确定替格瑞洛是否更有效。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits attention.

OBJECTIVE: To determine the association of ticagrelor vs clopidogrel with ischemic and hemorrhagic events in patients undergoing percutaneous coronary intervention (PCI) for ACS in clinical practice.

DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of patients with ACS who underwent PCI and received ticagrelor or clopidogrel was conducted using 2 United States electronic health record-based databases and 1 nationwide South Korean database from November 2011 to March 2019. Patients were matched using a large-scale propensity score algorithm, and the date of final follow-up was March 2019.

EXPOSURES: Ticagrelor vs clopidogrel.

MAIN OUTCOMES AND MEASURES: The primary end point was net adverse clinical events (NACE) at 12 months, composed of ischemic events (recurrent myocardial infarction, revascularization, or ischemic stroke) and hemorrhagic events (hemorrhagic stroke or gastrointestinal bleeding). Secondary outcomes included NACE or mortality, all-cause mortality, ischemic events, hemorrhagic events, individual components of the primary outcome, and dyspnea at 12 months. The database-level hazard ratios (HRs) were pooled to calculate summary HRs by random-effects meta-analysis.

RESULTS: After propensity score matching among 31 290 propensity-matched pairs (median age group, 60-64 years; 29.3% women), 95.5% of patients took aspirin together with ticagrelor or clopidogrel. The 1-year risk of NACE was not significantly different between ticagrelor and clopidogrel (15.1% [3484/23 116 person-years] vs 14.6% [3290/22 587 person-years]; summary HR, 1.05 [95% CI, 1.00-1.10]; P = .06). There was also no significant difference in the risk of all-cause mortality (2.0% for ticagrelor vs 2.1% for clopidogrel; summary HR, 0.97 [95% CI, 0.81-1.16]; P = .74) or ischemic events (13.5% for ticagrelor vs 13.4% for clopidogrel; summary HR, 1.03 [95% CI, 0.98-1.08]; P = .32). The risks of hemorrhagic events (2.1% for ticagrelor vs 1.6% for clopidogrel; summary HR, 1.35 [95% CI, 1.13-1.61]; P = .001) and dyspnea (27.3% for ticagrelor vs 22.6% for clopidogrel; summary HR, 1.21 [95% CI, 1.17-1.26]; P < .001) were significantly higher in the ticagrelor group.

CONCLUSIONS AND RELEVANCE: Among patients with ACS who underwent PCI in routine clinical practice, ticagrelor, compared with clopidogrel, was not associated with significant difference in the risk of NACE at 12 months. Because the possibility of unmeasured confounders cannot be excluded, further research is needed to determine whether ticagrelor is more effective than clopidogrel in this setting.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. You SC, Rho Y, Bikdeli B, et al. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA. 2020. PMID: 33107944. doi:10.1001/jama.2020.16167

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。